Stryker (NYSE:SYK) Stock Sale Revealed by Rep. Thomas H. Kean, Jr.

Posted by Alphonse Anthony on Nov 3rd, 2026

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on September 30th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 9/30/2026.
Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 9/29/2026.
Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 9/23/2026.
Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 9/17/2026.
Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 9/17/2026.
Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 8/27/2026.
Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
Sold $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 8/10/2026.

Stryker Price Performance

Shares of NYSE:SYK opened at $306.77 on Tuesday. The company has a market cap of $117.67 billion, a PE ratio of 32.67, a P/E/G ratio of 1.96 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The firm has a 50-day simple moving average of $292.37 and a 200 day simple moving average of $324.26. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same period in the prior year, the business earned $3.19 EPS. The business’s revenue was up 7.6% on a year-over-year basis. On average, sell-side analysts anticipate that Stryker Corporation will post 14.85 EPS for the current year.

Institutional Investors Weigh In On Stryker

Institutional investors and hedge funds have recently modified their holdings of the stock. United Advisor Group LLC boosted its stake in shares of Stryker by 18.2% during the 3rd quarter. United Advisor Group LLC now owns 929 shares of the medical technology company’s stock worth $256,000 after buying an additional 143 shares during the last quarter. Plancorp LLC increased its position in shares of Stryker by 11.7% in the third quarter. Plancorp LLC now owns 810 shares of the medical technology company’s stock valued at $236,000 after acquiring an additional 85 shares during the last quarter. Waycross Partners LLC bought a new stake in Stryker during the third quarter worth about $27,850,000. Alps Advisors Inc. raised its holdings in Stryker by 97.9% during the third quarter. Alps Advisors Inc. now owns 16,519 shares of the medical technology company’s stock worth $4,549,000 after acquiring an additional 8,173 shares in the last quarter. Finally, CenterBook Partners LP raised its holdings in Stryker by 129.5% during the third quarter. CenterBook Partners LP now owns 1,928 shares of the medical technology company’s stock worth $531,000 after acquiring an additional 1,088 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

SYK has been the subject of several recent research reports. Truist Financial restated a “hold” rating and set a $305.00 price target (down from $310.00) on shares of Stryker in a research report on Monday. Canaccord Genuity Group downgraded shares of Stryker from a “buy” rating to a “hold” rating and cut their price objective for the company from $385.00 to $300.00 in a research report on Friday. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a research note on Thursday. JPMorgan Chase & Co. decreased their target price on shares of Stryker from $350.00 to $340.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Royal Bank Of Canada dropped their price target on shares of Stryker from $420.00 to $375.00 and set an “outperform” rating on the stock in a research note on Friday. Sixteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $355.04.

View Our Latest Report on Stryker

Key Stryker News

Here are the key news stories impacting Stryker this week:

Positive Sentiment: JPMorgan maintained an Overweight rating despite reducing its price target from $350 to $340. The revised target still implies approximately 10.8% potential upside from the $306.77 reference price, providing a bullish counterpoint to the broader analyst caution. JPMorgan Stryker price target report
Positive Sentiment: Barclays reaffirmed its Buy rating, suggesting the firm continues to see long-term value in Stryker’s medical-device franchise despite resetting expectations. Barclays reaffirms Buy rating on Stryker
Neutral Sentiment: Investors are reviewing updated forecasts and fair-value estimates after Stryker’s third-quarter guidance prompted analysts to reset expectations. Stryker’s latest reported quarter also missed consensus revenue and earnings estimates, although revenue grew 7.6% year over year. Stryker stock forecast and price target Stryker fair value falls after Q3 guidance
Negative Sentiment: Truist reaffirmed a Hold rating and cut its target from $310 to $305, indicating limited near-term upside and a target slightly below the reference price. Truist Stryker rating and price target
Negative Sentiment: Additional target reductions from Citizens JMP, Citigroup, TD Cowen and Barclays, along with Canaccord Genuity’s downgrade to Hold, reinforce concerns that Stryker’s near-term valuation and growth outlook may be too optimistic. Citizens JMP cuts Stryker target Citigroup trims Stryker target TD Cowen cuts Stryker target Barclays cuts Stryker target Canaccord downgrades Stryker to Hold

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Insiders own 4.60% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Stryker

(Get Free Report)

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.